4 colonic L-cell sub-clusters, exhibiting differential expression of Gcg, Pyy (Peptide YY), Nts (neurotensin), Insl5 (insulin-like peptide 5), Cck (cholecystokinin), and Sct (secretin) @CamMetaboNet @MolMetab sciencedirect.com/science/articl nete a la conversacin
Sedenho-PradoLGYugarLBTWhitakerARMartinsMPJesusDCFerreiraIdSet alMetabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity: a systematic review and meta-analysis
1 Strong Weight Loss Supports Monthly GLP-1 Strategy The Phase 2b VESPER program evaluated weekly and monthly dosing in patients with obesity or overweight, with and without type 2 diabetes
The key is to use the lowest effective volume and frequency to correct the deficiency or meet the metabolic need, and to adjust as the patients condition improves
A meta-analysis covering over 28,000 patients found that while the overall rate of GI adverse events was similar (approximately 5253% of patients in both groups), serious adverse events occurred somewhat more frequently with higher tirzepatide doses (5.37% at 1015 mg) compared to semaglutide (2.8%)
